Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 18 · below the Ichimoku cloud · RSI 23 (oversold) · MACD below its signal
| 124.82 | 52-week high | +80.19% |
| 121.02 | Previous month high | +74.71% |
| 79.59 | Previous week high | +14.90% |
| 79.33 | Previous month low | +14.52% |
| 72.79 | R3 (classic) | +5.08% |
| 71.90 | R2 (classic) | +3.80% |
| 71.01 | Previous day high | +2.51% |
| 70.58 | R1 (classic) | +1.90% |
| 69.69 | Pivot | +0.61% |
| 69.27 | Price now | |
| 68.81 | Previous day low | −0.67% |
| 68.81 | Previous week low | −0.67% |
| 68.38 | S1 (classic) | −1.28% |
| 67.49 | S2 (classic) | −2.57% |
| 66.17 | S3 (classic) | −4.47% |
| 50.07 | 52-week low | −27.72% |
None of the 29 investors followed here reported a position in MNPR in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MNPR trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 30, 2026 | Starr Christopher MDirector | Conversion of Exercise of derivative security at price 0.00 per share. | 8.4K | $42 |
| Sep 30, 2026 | Starr Christopher MDirector | Sale at price 78.09 - 79.67 per share. | 8.4K | $659.39K |
| Sep 23, 2026 | Robinson Chandler DChief Executive Officer | Conversion of Exercise of derivative security at price 14.00 - 30.00 per share. | 29.1K | $631.68K |
| Sep 23, 2026 | Robinson Chandler DChief Executive Officer | Sale at price 87.15 - 89.79 per share. | 29.1K | $2.56M |
| Aug 25, 2026 | Tsuchimoto-Evans Kim RDirector | Conversion of Exercise of derivative security at price 14.00 - 30.00 per share. | 4.1K | $90.14K |
| Aug 25, 2026 | Rioux Patrice POfficer | Conversion of Exercise of derivative security at price 0.00 per share. | 1.4K | $7 |
| Aug 25, 2026 | Tsuchimoto-Evans Kim RDirector | Sale at price 108.83 - 113.84 per share. | 4.1K | $455.57K |
| Aug 25, 2026 | Rioux Patrice POfficer | Sale at price 111.26 per share. | 1 | $111 |
| Aug 24, 2026 | Anderson Raymond WilliamDirector | Conversion of Exercise of derivative security at price 30.00 per share. | 3.1K | $94.26K |
| Aug 24, 2026 | Anderson Raymond WilliamDirector | Sale at price 110.07 per share. | 646 | $71.11K |
| Aug 24, 2026 | Anderson Raymond WilliamDirector | Sale at price 110.04 - 113.05 per share. | 3.1K | $351.83K |
| Jun 29, 2026 | Robinson Chandler DChief Executive Officer | — | 12.9K | — |
| Jun 29, 2026 | Cittadine AndrewChief Operating Officer | — | 5.3K | — |
| Jun 29, 2026 | Vu Quan AnhChief Financial Officer | — | 1.2K | — |
| Mar 30, 2026 | Robinson Chandler DChief Executive Officer | — | 6.7K | — |
| Mar 30, 2026 | Cittadine AndrewChief Operating Officer | — | 3.5K | — |
| Dec 30, 2025 | Robinson Chandler DChief Executive Officer | — | 8.7K | — |
| Dec 30, 2025 | Cittadine AndrewChief Operating Officer | — | 4.3K | — |
| Dec 25, 2025 | Vu Quan AnhChief Financial Officer | Purchase at price 69.95 per share. | 1.5K | $104.92K |
| Dec 17, 2025 | Klausner Arthur JDirector | Sale at price 67.06 - 68.09 per share. | 5.1K | $343.89K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.5 | -9.2 | -0.0 | -4.8 | 24.7 | 42.4 | 17.0 | 3.3 | -28.8 | -13.1 | +6.1% | ||
| 2025 | 99.7 | -20.1 | 3.7 | 14.9 | -24.1 | 12.8 | 15.1 | -17.1 | 139.2 | 5.5 | 0.0 | -24.2 | +196.8% |
| 2024 | -1.2 | 147.0 | -18.0 | -3.1 | -7.4 | 19.5 | -4.1 | -31.7 | 182.0 | 116.2 | 54.6 | -2.4 | +1194.1% |
| 2023 | 51.1 | -12.6 | -55.6 | -19.1 | -13.1 | -12.6 | -13.3 | -12.8 | -4.0 | -30.6 | -32.6 | 17.2 | −85.7% |
| 2022 | -8.1 | 4.7 | -17.5 | -10.6 | -6.1 | 7.5 | -14.8 | -8.2 | -15.6 | 61.8 | 4.5 | -7.8 | −26.2% |
| 2021 | 38.1 | -13.6 | -15.1 | -3.1 | -5.0 | 3.2 | -9.8 | -2.6 | -5.8 | -1.4 | -8.3 | -27.1 | −47.5% |
| 2020 | -13.6 | -33.1 | -25.4 | 2.7 | 4.6 | -3.1 | -1.6 | -23.0 | -5.3 | -17.1 | 9.9 | 25.4 | −63.1% |
| 2019 | — |
TimeframesUp on the monthly, down on the hourly and daily, mixed on the weekly.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
over a rising 21 EMA, 21 over 50
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Buy / hold / sell counts